MCu(II)-diacetyl-bis(A-methyl-thiosemicarbazone) (64Cu-ATSM) has been proposed as a positron emitting radiotracer to delineate tumour hypoxia using positron emission tomography (PET). In this study evaluation of this radiotracer was carried out in the P22 carcinosarcoma BD-9 rat tumour model. The distribution of 64Cu-ATSM with the immunohistochemical marker of hypoxia, pimonidazole, was compared using autoradiography and pimonidazole staining at early (1 hour) and late (20.5 hours) time-points after tracer injection however no correlation was found. The impact of tumour blood flow in determining tumour distribution of 64Cu-ATSM Gadolinium- enhanced MRI scanning was investigated. This showed a correlation between 64Cu- ATSM and blood flow up...
Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent ...
Background: Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124I-io...
The most common and aggressive primary malignancy of the central nervous system is Glioblastoma that...
International audienceMapping tumor hypoxia is a great challenge in positron emission tomography (PE...
During the carcinogenesis process, tumour cells often have a more rapid proliferation potential than...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
We showed previously that, in vitro, copper-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) uptak...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Background Tumor hypoxia (low tissue oxygenation) is an adverse condition of the solid tumor environ...
ObjectiveHypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical...
(64)Cu-diacetyl-bis(N(4)-methylthiosemicarbazonate), (64)Cu-ATSM, continues to be investigated clini...
Purpose Cu-62labeled diacetyl-bis (N(4)-methylthiosemicarbaone) (Cu-62-ATSM) is a well-knownhypoxic ...
Introduction—Cu-ATSM, a hypoxia imaging agent, has been shown to be predictive of response to tradit...
CERVOXY/LDM TEPInternational audienceBackground: Diacetyl-bis(N4-methylthiosemicarbazone), labeled w...
[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu]ATSM) was prepared using in house-made diacety...
Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent ...
Background: Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124I-io...
The most common and aggressive primary malignancy of the central nervous system is Glioblastoma that...
International audienceMapping tumor hypoxia is a great challenge in positron emission tomography (PE...
During the carcinogenesis process, tumour cells often have a more rapid proliferation potential than...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
We showed previously that, in vitro, copper-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) uptak...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Background Tumor hypoxia (low tissue oxygenation) is an adverse condition of the solid tumor environ...
ObjectiveHypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical...
(64)Cu-diacetyl-bis(N(4)-methylthiosemicarbazonate), (64)Cu-ATSM, continues to be investigated clini...
Purpose Cu-62labeled diacetyl-bis (N(4)-methylthiosemicarbaone) (Cu-62-ATSM) is a well-knownhypoxic ...
Introduction—Cu-ATSM, a hypoxia imaging agent, has been shown to be predictive of response to tradit...
CERVOXY/LDM TEPInternational audienceBackground: Diacetyl-bis(N4-methylthiosemicarbazone), labeled w...
[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu]ATSM) was prepared using in house-made diacety...
Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent ...
Background: Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124I-io...
The most common and aggressive primary malignancy of the central nervous system is Glioblastoma that...